StreetInsider.com News Articles

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.

Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

Thu, 21 May 2026 10:23:00 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck & Co. (NYSE: MRK) and Eisai announced that their Phase 3 LITESPARK-012 trial evaluating combination treatments for advanced renal cell carcinoma did not meet its primary endpoints of progression-free survival and overall survival.

The trial tested two experimental combination regimens against the established treatment of Keytruda plus Lenvima in 1,688 patients with advanced clear cell renal cell carcinoma. One combination included Keytruda, Lenvima, and Welireg, while the other tested MK-1308A plus Lenvima.

At a pre-specified interim analysis, neither experimental combination demonstrated superior efficacy compared to the control arm of Keytruda plus Lenvima for first-line treatment. The companies reported that safety profiles

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck and Eisai report failed kidney cancer drug trial results

Tue, 21 Apr 2026 08:37:34 -0400

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC

Tue, 21 Apr 2026 06:52:00 -0400

TOKYO and RAHWAY, N.J., Apr 21, 2026 - (JCN Newswire) - - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced results from the Phase 3 LITESPARK-012 trial evaluating combination treatments for the firstline treatment of patients with advanced clear cell renal cell carcinoma (RCC). The trial evaluated the triplet therapy of KEYTRUDA(R) (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, plus LENVIMA(R) (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, plus WELIREG(R) (belzutifan), Merck

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC

Tue, 21 Apr 2026 06:52:00 -0400